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Editorial Perspective

This article presents an important status check on the more
recent literature regarding the continuing global health care
concern about tuberculosis (TB), as related to its spinal manifestations in the form of Pott’s disease.
In the big picture, TB remains one of the top 10 causes of
death globally, with 1.8 million deaths reported in 2015.1 The
gold-standard TB treatment remains long-term antibiotic therapy with spine surgical indications essentially unchanged since
the MRC trials (1940-1949).2 The optimism towards medical
eradication of TB, with a reported annual decline of about 1.5%
per year since 2000, has been tempered by the emergence of
multidrug-resistant (MDR) variants in regards to treatability,
affordability, and likely further disease spread. In 2015, the
World Health Organization (WHO) reported 10.4 million new
cases with about 480 000 of them MDR cases.1 Multidrugresistant cases are noteworthy for their much increased burden
of care requirements, including much higher treatment costs
(US$18 000 for a 6 month course of treatment for conventional
TB versus US$134 000 for MDR to US$430 000 for extensively resistant variants), and more common inpatient care and
lost productivity over the 2 year treatment period needed.3
These circumstances bode poorly for future disease containment efforts. While this review article does not address the
changing resistance patterns of TB, it does reflect the global
presence of the disease in its publication profile. Sixty percent
of new TB cases occur in India, Indonesia, China, Nigeria,
Pakistan, and South Africa, as reflected by the publications
list.1 As the graphic representations show, China increasingly
dominates the world literature over the last 2 years (with no
publications on surgical treatment of Pott’s disease from the
United States since 2000, despite approximately 10 000 new
TB cases per year).2 Extensive representation of medical literature from one cultural sphere may be problematic, as experiences from one country may not translate to the sociocultural
norms and resources available in another part of the world.

In general, the authors could not answer the question of if
there is a change in surgical treatment indications for Pott’s
disease and overall prevalence of surgery. Based on the summary findings, it appears that posteriorly based surgery is
becoming the preferred approach for adults. In terms of outcomes and results reporting, there remains a high degree of
uncertainty. The authors present an inventory list of key deliverables, which would seem to be of interest for all spinal TB
related studies, yet only a paucity of studies actually address
these parameters. Most importantly, perhaps, length of followup and longer-term assessment of recurrence in these patients is
still mostly unknown.
Given these limitations, it is hard to gauge the present-day
outcomes of spine surgery for TB and if there have been tangible improvements for patients. Hopefully, authors on the
topic of Pott’s disease will include these key variables in their
studies going forward to allow for greater comparability of
results across centers and regions of the world.
Jens. R. Chapman
Swedish Medical Center, Seattle, WA, USA
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